Hot medicines: stability of protein-based medicines
Developing countries are for a large part dependent on western countries for their medicines. A large part of those medicines contain therapeutic proteins that are sensitive to tropical conditions which decrease or completely nullify their effectiveness.

The constant cooling during transport, however, is rather expensive and not always a possibility. This project aims to develop ways to stabilize the proteins in these medicines under tropical conditions without a significant increase in development costs. The focus of this project is on the World Health Organization priority medicines: oxytocin and insulin as well as vaccines for influenza. So far a major breakthrough has been achieved for oxytocin which can now be kept stabile at forty degrees Celsius. For influenza a stabilizing factor has been found as well, possibly leading to a new stabile formulation.

Fast facts
Full project title: Hot medicines: breaking the cold chain requirement for polypeptide-based priority medicines
Start date: December 2006
End date: February 2012
Goal: Develop drug formulations that are stable under tropical conditions
Principal investigator: Wouter Hinrichs
Project size: 2,3 FTE's
Partners: Abbott, MSD, Leiden University, OctoPlus NV, University of Groningen

PhD theses from this project

“TI Pharma's partnerships result in a synergy that really drives the science further than the individual parties could achieve working alone.”

Jan Raaijmakers
Past VP External Scientific Collaborations GSK Europe
Chair TI Pharma Board of Directors

Share this page: